A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

NCT02616185

Last updated date
Study Location
Morristown Medical Center
Morristown, New Jersey, 07960, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Prostatic Neoplasms
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological or cytological diagnosis of prostate cancer

- Adequate bone marrow, kidney and liver function

- Hormone sensitive relapsing prostate cancer after definitive local therapy (biochemical relapse) OR

- Failed prior therapy with a novel hormone (e.g. enzalutamide, abiraterone) with documented progressive disease (post-novel hormone therapy CRPC)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- ECOG performance status greater than or equal to 2


- Concurrent immunotherapy for prostate cancer


- History of or active autoimmune disorders (including but not limited to: myasthenia
gravis, thyroiditis, pneumonitis, rheumatoid arthritis, multiple sclerosis, systemic
lupus erythematosus, scleroderma) and other conditions that disorganize or alter the
immune system.


- History of inflammatory bowel disease.


- Current use of any implanted electronic stimulation device


- For biochemically relapsed patients, no concurrent use of ADT or orchiectomy and no
known prior or current evidence of any metastatic involvement of distant organs


- For post-novel hormone patients, no concurrent treatment with a secondary hormone
(e.g. enzalutamide, abiraterone), no metastasis to the liver or brain

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Prostatic NeoplasmsStudy Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer NCT00137436
  1. Harvey, Illinois
  2. Tinley Park, Illinois
  3. Hobart, Indiana
  4. Munster, Indiana
  5. Durham, North Carolina
  6. Portland, Oregon
  7. Portland, Oregon
  8. Myrtle Beach, South Carolina
  9. Clarksville, Tennessee
  10. Franklin, Tennessee
  11. Gallarin, Tennessee
  12. Hermitage, Tennessee
  13. Lebanon, Tennessee
  14. Murfreesboro, Tennessee
  15. Nashville, Tennessee
  16. Nashville, Tennessee
  17. Nashville, Tennessee
  18. Nashville, Tennessee
  19. Smithville, Tennessee
  20. Smyrna, Tennessee
  21. Tullahoma, Tennessee
  22. Dallas, Texas
  23. Houston, Texas
  24. Madison, Wisconsin
Male
18 Years+
years
MULTIPLE SITES
Prostatic NeoplasmsAn Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients NCT00235794
  1. Houston, Texas
Male
18 Years+
years
MULTIPLE SITES
Prostatic NeoplasmsA Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) NCT02616185
  1. Morristown, New Jersey
  2. Whippany, New Jersey
  3. Tucson, Arizona
  4. Tucson, Arizona
  5. Golden, Colorado
  6. New Haven, Connecticut
  7. Bethesda, Maryland
  8. Bethesda, Maryland
  9. Creve Coeur, Missouri
  10. Saint Louis, Missouri
  11. Saint Louis, Missouri
  12. Saint Louis, Missouri
  13. Omaha, Nebraska
  14. Las Vegas, Nevada
  15. Morristown, New Jersey
  16. Morristown, New Jersey
  17. Rockaway, New Jersey
  18. Lake Success, New York
  19. New York, New York
  20. New York, New York
  21. New York, New York
  22. New York, New York
  23. Durham, North Carolina
  24. Durham, North Carolina
  25. Pittsburgh, Pennsylvania
  26. Seattle, Washington
  27. Seattle, Washington
Male
18 Years+
years
MULTIPLE SITES
Prostatic NeoplasmsStudy of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) NCT00313781
  1. Los Angeles, California
  2. New York, New York
  3. Cleveland, Ohio
  4. Cleveland, Ohio
  5. Orange Village, Ohio
  6. Philadelphia, Pennsylvania
  7. Montreal, Quebec
  8. Montreal, Quebec
  9. Berlin,
  10. Muenchen,
  11. Hospitalet de Llobregat, Barcelona
  12. A Coruña,
  13. Barcelona,
  14. St. Gallen,
  15. Sutton, Surrey
  16. Glasgow,
  17. Glasgow,
  18. Guildford,
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Official Title  ICMJE A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)
Brief Summary The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostatic Neoplasms
Intervention  ICMJE
  • Biological: PF-06755992
    PF-06755992 will be administered on Day 1 of each cycle. Two dose levels will be evaluated.
    Other Name: AdC68
  • Biological: PF-06755990
    PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
    Other Name: pDNA
  • Device: TDS-IM Electroporation Device
    TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
  • Biological: Tremelimumab
    PF-06753388 will be administered every 28 days.
    Other Name: PF-06753388
  • Drug: Sunitinib
    Sunitinib will be taken daily. Up to three dose levels may be evaluated to determine MTD when given in combination with PrCa VBIR.
  • Biological: PF-06801591
    PF-06801591 will be administered every 28 days.
  • Biological: PF-06753512
    Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
    Other Name: VBIR-1
Study Arms  ICMJE Experimental: Dose Escalation
PF-06753512
Interventions:
  • Biological: PF-06755992
  • Biological: PF-06755990
  • Device: TDS-IM Electroporation Device
  • Biological: Tremelimumab
  • Drug: Sunitinib
  • Biological: PF-06801591
  • Biological: PF-06753512
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 30, 2020)
160
Original Estimated Enrollment  ICMJE
 (submitted: November 24, 2015)
78
Estimated Study Completion Date  ICMJE February 11, 2023
Estimated Primary Completion Date February 11, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histological or cytological diagnosis of prostate cancer
  • Adequate bone marrow, kidney and liver function
  • Hormone sensitive relapsing prostate cancer after definitive local therapy (biochemical relapse) OR
  • Failed prior therapy with a novel hormone (e.g. enzalutamide, abiraterone) with documented progressive disease (post-novel hormone therapy CRPC)

Exclusion Criteria:

  • ECOG performance status greater than or equal to 2
  • Concurrent immunotherapy for prostate cancer
  • History of or active autoimmune disorders (including but not limited to: myasthenia gravis, thyroiditis, pneumonitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma) and other conditions that disorganize or alter the immune system.
  • History of inflammatory bowel disease.
  • Current use of any implanted electronic stimulation device
  • For biochemically relapsed patients, no concurrent use of ADT or orchiectomy and no known prior or current evidence of any metastatic involvement of distant organs
  • For post-novel hormone patients, no concurrent treatment with a secondary hormone (e.g. enzalutamide, abiraterone), no metastasis to the liver or brain
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Gender Based Eligibility:Yes
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02616185
Other Study ID Numbers  ICMJE B7791001
PRCA VBIR FIP STUDY ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP